The keystone of precision medicine in complex traits is to predict the onset and progression of the disease. While there are different paths toward precision medicine [
1], genetic assessment may be among the top strategies. The current knowledge of the complete human genome sequence and the availability of next-generation sequencing technologies [
2] to decipher individual patients’ genetic make-up also invite fully integrated genomic medicine. Therefore, patients may be classified into high or low risk for disease onset or severity, and therapeutic interventions can be personalized. Most importantly, precision medicine must ensure health benefits across geography, ethnicity, age, and gender.
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease whose prevalence has reached global epidemic proportions in adults and children [
3]. Once diagnosed, the treatment of NAFLD is complex and often requires pharmacological intervention to treat the liver disease and its associated risk factors, such as obesity, arterial hypertension, insulin resistance, and abnormal circulating lipid profiles [
4]. Hence, in this complex scenario, NAFLD presents myriad challenges to physicians, researchers, and patients.
With advances in the genetic knowledge of NAFLD and nonalcoholic steatohepatitis (NASH) [
1,
5,
6], it has become possible to use the information for clinical application. For example, genetic data could be leveraged to identify individuals who are at risk of NAFLD or estimate the risk of severe histological outcomes, including NASH-fibrosis, cirrhosis, and hepatocellular carcinoma [
5].
The biological information gained through the years should be integrated with clinical data and translated into efficient, cost-effective, and reliable decision-making. This bioinformatics integration increases efficiency in the clinical setting and improves diagnosis, ultimately facilitating disease monitoring and therapeutics while also saving healthcare costs.
Major NAFLD-associated gene variants function in metabolic pathways, including substrate delivery for de novo lipogenesis, mitochondrial energy utilization, lipid droplet assembly, lipolytic catabolism, fatty acid compartmentalization very low density lipoprotein assembly, and secretion pathways [
6]. However, variants in some genes, such as rs738409 in
PNPLA3 and rs58542926 in
TM6SF2, present pleiotropic associations that can even explain some systemic effects on emerging diseases, such as COVID-19 [
7]. Pleiotropy analysis in a recent genome-wide association study of unexplained chronic alanine aminotransferase elevation as a proxy for NAFLD revealed that several replicated variants were jointly associated with metabolic and/or inflammatory traits, revealing a complex model of genetic architecture [
8].
In addition, genetic knowledge integration, data modeling, and analysis are vital processes at the interface with drug discovery. However, drug discovery and precision medicine require a complete understanding of new technologies and gene and protein biology of the selected target [
1].
A unique approach to advancing the identification of genetic factors associated with NAFLD is, for instance, the discovery of disease-specific eQTL (expression quantitative trait loci) [
9]. This approach has shown that the rs2291702 variant located in alanine--glyoxylate aminotransferase 2 (
AGXT2) gene protects against liver fibrosis in a genotype-dependent manner with the potential for therapeutic interventions [
9].
Although the heritability of NAFLD is ~50%, as in other complex diseases, a significant proportion of the disease burden remains unexplained; the so-called “the missing heritability” [
1,
5]. The concept of the missing heritability includes not only the genetic and epigenetic modifiers [
10], but the interaction with environmental exposure and diet [
11], as well as highly interconnected and dynamic factors, such as the liver microbiome [
12]. Some examples of the poorly explored heritability estimates of NAFLD and NASH that explain the disease variance are rare variants, which probably would have substantial effects on the phenotype, the exploration of structural variation, the assessment of interaction among the involved loci-also known as epistasis, and the genetic diversity of the mitochondrial DNA, among many others [
5].
Recently, a human study demonstrated that the variants influencing the risk/protection against NAFLD-histological severity (
PNPLA3-rs738409,
TM6SF2-rs58542926,
MBOAT7-rs641738, and
HSD17B13-rs72613567) and a variant influencing macronutrient intake (
FGF21-rs838133) may affect the liver microbial DNA composition [
13]. The significant variants’ combined effect associated with a polygenic risk score (PRS) suggested a link between the liver metataxonomic profile, host genetics, and cardiovascular risk [
13].
The ultimate goal of precision medicine is to estimate the patient’s risk of developing a particular disease. In this regard, PRS is a valuable instrument for stratifying the population risk according to the individual’s genetic profile. However, some challenges remain, including the missing heritability, discovery of rare variants [
14,
15], and reproducibility of GWAS findings in diverse populations [
1]. On the other hand, there is the advantage of potentially distinguishing patients with high or low risk of severe disease [
1]. Although outside of the focus of this snapshot, the advances in transcriptomics, proteomics, and metabolomics integrated with genomics in a multi-omics approach [
16] are presenting a fascinating scenario for the personalized medicine of NAFLD and comorbidities.
In conclusion, the newly acquired genetic information should be used to improve the understanding of disease pathogenesis, which may allow the early identification of at-risk patients, who would benefit most from early treatment. Potential avenues for future research should focus on the prevention, surveillance, and prognosis assessment of NAFLD and NASH. The ultimate role of precision therapy relies on defining the appropriate prediction strategies for implementing patient-based therapies.
FOOTNOTES
-
Authors’ contributions
C.J.P Concept of the work, manuscript writing and approval. S.S. Concept of the work, manuscript writing and approval.
-
Conflicts of Interest
The authors have no conflicts to disclose.
Abbreviations
alanine--glyoxylate aminotransferase 2
expression quantitative trait loci
nonalcoholic fatty liver disease
nonalcoholic steatohepatitis
REFERENCES
- 1. Sookoian S, Pirola CJ. Precision medicine in nonalcoholic fatty liver disease: new therapeutic insights from genetics and systems biology. Clin Mol Hepatol 2020;26:461-475.
- 2. Salatino A, Sookoian S, Pirola CJ. Computational pipeline for next-generation sequencing (NGS) studies in genetics of NASH. Methods Mol Biol 2022;2455:203-222.
- 3. Brunt EM, Wong VW, Nobili V, Day CP, Sookoian S, Maher JJ, et al. Nonalcoholic fatty liver disease. Nat Rev Dis Primers 2015;1:15080.
- 4. Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med 2018;24:908-922.
- 5. Sookoian S, Pirola CJ. Genetics of nonalcoholic fatty liver disease: from pathogenesis to therapeutics. Semin Liver Dis 2019;39:124-140.
- 6. Sookoian S, Pirola CJ, Valenti L, Davidson NO. Genetic pathways in nonalcoholic fatty liver disease: insights from systems biology. Hepatology 2020;72:330-346.
- 7. Pirola CJ, Sookoian S. PNPLA3 and COVID-19 outcomes: thinking outside the box might explain the biology behind pleiotropic effects of rs738409 on the immune system. Liver Int 2021;41:2801-2804.
- 8. Vujkovic M, Ramdas S, Lorenz KM, Guo X, Darlay R, Cordell HJ, et al. A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation. Nat Genet 2022;54:761-771.
- 9. Yoo T, Joo SK, Kim HJ, Kim HY, Sim H, Lee J, et al. Disease-specific eQTL screening reveals an anti-fibrotic effect of AGXT2 in non-alcoholic fatty liver disease. J Hepatol 2021;75:514-523.
- 10. Pirola CJ, Sookoian S. Metabolic dysfunction-associated fatty liver disease: advances in genetic and epigenetic implications. Curr Opin Lipidol 2022;33:95-102.
- 11. Vilar-Gomez E, Pirola CJ, Sookoian S, Wilson LA, Belt P, Liang T, et al. Impact of the association between PNPLA3 genetic variation and dietary intake on the risk of significant fibrosis in patients with NAFLD. Am J Gastroenterol 2021;116:994-1006.
- 12. Sookoian S, Salatino A, Castaño GO, Landa MS, Fijalkowky C, Garaycoechea M, et al. Intrahepatic bacterial metataxonomic signature in non-alcoholic fatty liver disease. Gut 2020;69:1483-1491.
- 13. Pirola CJ, Salatino A, Quintanilla MF, Castaño GO, Garaycoechea M, Sookoian S. The influence of host genetics on liver microbiome composition in patients with NAFLD. EBioMedicine 2022;76:103858.
- 14. Baselli GA, Jamialahmadi O, Pelusi S, Ciociola E, Malvestiti F, Saracino M, et al. Rare ATG7 genetic variants predispose patients to severe fatty liver disease. J Hepatol 2022;77:596-606.
- 15. Pirola CJ, Flichman D, Dopazo H, Fernández Gianotti T, San Martino J, Rohr C, et al. A rare nonsense mutation in the glucokinase regulator gene is associated with a rapidly progressive clinical form of nonalcoholic steatohepatitis. Hepatol Commun 2018;2:1030-1036.
- 16. Pirola CJ, Sookoian S. Multiomics biomarkers for the prediction of nonalcoholic fatty liver disease severity. World J Gastroenterol 2018;24:1601-1615.
Citations
Citations to this article as recorded by
- Mapping the genomic landscape of MASLD: A framework for molecular subtyping and precision hepatology
Carlos José Pirola, Silvia Sookoian
Med.2026; 7(6): 101131. CrossRef - Hidden in the Fat: Unpacking the Metabolic Tango Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Syndrome
Mariana Boulos, Rabia S. Mousa, Nizar Jeries, Elias Simaan, Klode Alam, Bulus Bulus, Nimer Assy
International Journal of Molecular Sciences.2025; 26(7): 3448. CrossRef - Correspondence to editorial on “Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C”
Tom Ryu, Young Chang, Seung Up Kim, Jae Young Jang
Clinical and Molecular Hepatology.2025; 31(2): e203. CrossRef - Single-cell eQTL analysis identifies genetic variation underlying metabolic dysfunction-associated steatohepatitis
Sung Eun Hong, Seon Ju Mun, Young Joo Lee, Taekyeong Yoo, Kyung-Suk Suh, Keon Wook Kang, Myung Jin Son, Won Kim, Murim Choi
Nature Genetics.2025; 57(7): 1638. CrossRef - Biomarker-Driven Optimization of Saponin Therapy in MASLD: From Mouse Models to Human Liver Organoids
Hye Young Kim, Ju Hee Oh, Hyun Sung Kim, Dae Won Jun
Antioxidants.2025; 14(8): 943. CrossRef - Non-invasive tests of fibrosis in the management of MASLD: revolutionising diagnosis, progression and regression monitoring
Gong Feng, Vincent Wai-Sun Wong, Giovanni Targher, Christopher D Byrne, Ming-Hua Zheng
Gut.2025; 74(10): 1741. CrossRef - Endoscopic sleeve gastrectomy vs traditional bariatric surgery: A paradigm shift in managing metabolic dysfunction-associated steatohepatitis and cirrhosis?
David Jerez Diaz, Rishi Devaraja Vattikuti, Allison Janak, Anuroop Yekula, Priya Farooq, Asad Ullah, Truptesh H Kothari, Shivangi Kothari, Vivek Kaul, Patrick Twohig
World Journal of Gastrointestinal Pharmacology and Therapeutics.2025;[Epub] CrossRef - Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD)
Raquel Benedé-Ubieto, Francisco Javier Cubero, Yulia A. Nevzorova
Gut Microbes.2024;[Epub] CrossRef - Editorial: Redefining liver health—Personalised approach to assessment of serum ALT in clinical practice. Authors' reply
Eunice X. X. Tan, Daniel Q. Huang, Mindie H. Nguyen
Alimentary Pharmacology & Therapeutics.2024; 60(3): 411. CrossRef - Genetics of Metabolic Dysfunction-associated Steatotic Liver Disease: The State of the Art Update
Silvia Sookoian, Yaron Rotman, Luca Valenti
Clinical Gastroenterology and Hepatology.2024; 22(11): 2177. CrossRef - Ex Vivo Tools and Models in MASLD Research
Rallia-Iliana Velliou, Eirini Giannousi, Christiana Ralliou, Eva Kassi, Antonios Chatzigeorgiou
Cells.2024; 13(22): 1827. CrossRef - Advancements in Non-Alcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Treatment: From Lifestyle Interventions to Novel Therapies
Mehrab Manteghian
University of Toronto Medical Journal.2024;[Epub] CrossRef - Advances in our understanding of the molecular heterogeneity of fatty liver disease: toward informed treatment decision making
Carlos J Pirola, Silvia Sookoian
Expert Review of Gastroenterology & Hepatology.2023; 17(4): 317. CrossRef - Genetics in non-alcoholic fatty liver disease: The role of risk alleles through the lens of immune response
Silvia Sookoian, Carlos J. Pirola
Clinical and Molecular Hepatology.2023; 29(Suppl): S184. CrossRef - The effects of moderate alcohol consumption on non-alcoholic fatty liver disease
Hyunwoo Oh, Won Sohn, Yong Kyun Cho
Clinical and Molecular Hepatology.2023; 29(Suppl): S261. CrossRef
